Compass Therapeutics' (CMPX) Tovecimig Drives Strong Analyst Sentiment [Yahoo! Finance]
Compass Therapeutics, Inc. (CMPX)
Company Research
Source: Yahoo! Finance
On December 3, 2025, Compass Therapeutics, Inc. (NASDAQ:CMPX) saw Canaccord analyst John Newman initiate coverage of the stock with a “Buy” rating and a $10 price target. The analyst attributed the bullish stance to positive data in the first quarter of 2026 from second-line biliary tract cancer studies. Newman sees tovecimig as the central value driver, alongside additional clinical-stage assets that hold potential to support longer-term diversification. Compass Therapeutics, Inc. (NASDAQ:CMPX) was also revisited by Citizens JMP analyst Reni Benjamin the same day, who initiated coverage with an “Outperform” rating and a $10 price target. Reported by The Fly, Benjamin cited recent data from a pivotal Phase 2/3 study. The data showed a 17% overall response rate for tovecimig in combination with paclitaxel in biliary tract cancers, versus 5% in the paclitaxel-only arm. This reinforces the program's clinical momentum, the analyst noted. In its Q3 2025 update, management provided fur
Show less
Read more
Impact Snapshot
Event Time:
CMPX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CMPX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CMPX alerts
High impacting Compass Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CMPX
News
- Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare ConferenceGlobeNewswire
- Compass Therapeutics, Inc. (CMPX) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Compass Therapeutics (NASDAQ:CMPX) is now covered by analysts at Citizens Jmp. They set an "outperform" rating and a $10.00 price target on the stock.MarketBeat
- Compass Therapeutics (NASDAQ:CMPX) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $10.00 price target on the stock.MarketBeat
- Compass Therapeutics (NASDAQ:CMPX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.MarketBeat
CMPX
Earnings
- 8/11/25 - Miss
CMPX
Sec Filings
- 11/18/25 - Form 4
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- CMPX's page on the SEC website